Sarah J. Skuli, MD, PhD

Skuli S.; Matthews A.; Carroll M.; Lai C. 12-01-2024. A line in shifting sand: Can we define and target TP53 mutated MDS? Seminars in Hematology, 61 6, 449-456

Bosc C.; Broin N.; Fanjul M.; Saland E.; Farge T.; Courdy C.; Batut A.; Masoud R.; Larrue C.; Skuli S.; Espagnolle N.; Pagès J.C.; Carrier A.; Bost F.; Bertrand-Michel J.; Tamburini J.; Récher C.; Bertoli S.; Mansat-De Mas V.; Manenti S.; Sarry J.E.; Joffre C. 12-01-2020. Autophagy regulates fatty acid availability for oxidative phosphorylation through mitochondria-endop Nature Communications, 11 1,

Pottier A.; Park S.; Lee Y.; Liccardo F.; Yang H.; Park J.; Lorant A.; Schnekenburger M.; Brusa D.; Li V.; Valente S.; Mai A.; Skuli S.J.; Carroll M.; Boettcher S.; Sarry J.E.; Cerella C.; Morceau F.; Diederich M. 11-28-2025. TP53-agnostic lethality through combined pan-HDAC and CDK inhibition in acute myeloid leukemia Cancer Letters, 633 ,

Freyer C.W.; Bange E.M.; Skuli S.; Hsu M.; Lin J.; Cuker A.; Cohen A.D.; Garfall A. 11-01-2021. Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome in a Patient With Heterozygous CFHR3/CFHR1 De Clinical Lymphoma Myeloma and Leukemia, 21 11, e845-e849

Skuli S.J.; Bakayoko A.; Kruidenier M.; Manning B.; Pammer P.; Salimov A.; Riley O.; Brake-Sillá G.; Dopkin D.; Bowman M.; Martinez-Gutierrez L.N.; Anderson C.C.; Reisz J.A.; Buono R.; Paul M.; Saland E.; Liccardo F.; DeVine A.; Wong S.; Xu J.P.; Nee E.; Hausler R.; Boettcher S.; Sebti S.M.; Lai C.; Maxwell K.N.; Sarry J.E.; Fruman D.A.; D’Alessandro A.; Mesaros C.; Keith B.; Simon M.C.; Sung P.J.; Wertheim G.; Skuli N.; Bowman R.L.; Matthews A.; Carroll M. 09-01-2025. Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgera Leukemia, 39 9, 2087-2098

Senagolage M.D.; Blaylock H.Z.; Khan S.; Skuli S.J.; Carroll M.P.; McNerney M.E. 08-01-2025. NAMPT haploinsufficiency is a collateral lethal therapeutic vulnerability in high-risk myeloid malig Blood Neoplasia, 2 3,

Matthews A.H.; Perl A.E.; Luger S.M.; Gill S.I.; Lai C.; Porter D.L.; Skuli S.; Bruno X.J.; Carroll M.P.; Freyer C.W.; Carulli A.; Babushok D.V.; Frey N.V.; Hexner E.O.; Martin M.E.; McCurdy S.R.; Stadtmauer E.A.; Loren A.W.; Paralkar V.R.; Maillard I.P.; Pratz K.W. 08-01-2023. Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylatin American Journal of Hematology, 98 8, 1254-1264

Zhang P.; Whipp E.C.; Skuli S.J.; Gharghabi M.; Saygin C.; Sher S.A.; Carroll M.; Pan X.; Eisenmann E.D.; Lai T.H.; Harrington B.K.; Chan W.K.; Youssef Y.; Chen B.; Penson A.; Lewis A.M.; Castro C.R.; Fox N.; Cihan A.; Le Luduec J.B.; DeWolf S.; Kauffman T.; Mims A.S.; Canfield D.; Phillips H.; Williams K.E.; Shaffer J.; Lozanski A.; Doong T.J.; Lozanski G.; Mao C.; Walker C.J.; Blachly J.S.; Daniyan A.F.; Alinari L.; Baiocchi R.A.; Yang Y.; Grieselhuber N.R.; Campbell M.J.; Baker S.D.; Blaser B.W.; Abdel-Wahab O.; Lapalombella R. 05-15-2025. TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppress Journal of Clinical Investigation, 135 10,

Skuli S.J.; Alomari S.; Gaitsch H.; Bakayoko A.; Skuli N.; Tyler B.M. 05-01-2022. Metformin and Cancer, an Ambiguanidous Relationship Pharmaceuticals, 15 5,

Skuli S.J.; Sheng J.Y.; Bantug E.T.; Zafman N.; Riley C.; Ruck J.M.; Smith K.C.; Snyder C.F.; Smith K.L.; Stearns V.; Wolff A.C. 02-15-2019. Survivorship care visits in a high-risk population of breast cancer survivors Breast Cancer Research and Treatment, 173 3, 701-708

Sheng J.Y.; Skuli S.J.; Thorner E.D.; Zafman N.; Riley C.D.; Ruck J.M.; Smith K.C.; Snyder C.; Smith K.L.; Stearns V.; Wolff A.C. 02-01-2022. Late effects in a high-risk population of breast cancer survivors Supportive Care in Cancer, 30 2, 1749-1757

Mahdavi L.; Alikarami F.; Goodrow H.; Lenard A.; Riedel S.S.; Libbrecht C.; Bowser I.; Tasian S.K.; Falkenstein C.D.; Manning B.; Skuli S.; Carroll M.P.; Wertheim G.; Cai S.F.; McGeehan G.; Yu S.; Shi J.; Xie H.M.; Bernt K.M. 01-01-2026. Upfront menin-inhibitor resistance in multiply pretreated leukemias Experimental Hematology, 153 ,

Boët E.; Saland E.; Skuli S.; Griessinger E.; Sarry J.E. 01-01-2024. Mitohormesis: The keystone of therapeutic resistance in cancer cells Comptes Rendus Biologies, 347 , 59-75

Matthews A.; Fenu E.; Skuli S.J.; Harris J.C.; Bagg A.; Lai C. 01-01-2024. Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high s Leukemia and Lymphoma, 65 7, 1012-1015